ALX Oncology Holdings Inc.

NASDAQ:ALXO

Biotechnology

Healthcare
$0.97 -2.12%

-$0.03 today

Market cap
$134.14M
Beta
0.45
P/E (TTM)
-0.9
EPS (TTM)
-$1.64
52W Low $0.40High $2.66

Volume 0.56M

Average 1.07M

Returns on capital

ALX Oncology Holdings Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-391.4%

avg 768.3%

ROIC

-262.0%

avg -126.9%

ROA

-172.2%

avg -88.2%

Analysis

ROA is currently the strongest return metric at -172.2% versus its period average of -88.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Jason W. Lettmann

Chief Executive Officer & DirectorUSD 1.02M49——

Harish Shantharam

Chief Financial OfficerUSD 642.87K45303.00K0.23%

Shelly Wong

Senior Vice President of Finance & Chief Accounting OfficerUSD 578.47K5087.83K0.07%

Barbara J. Klencke

Chief Medical OfficerUSD 262.58K69——

Athanasios Tsiatis

Senior Vice President of Clinical Development————

Lin Yeong-Liang

Senior Vice President of Drug Safety & Pharmacovigilance————

Michael Listgarten

General Counsel————

Lisa Sauer

Senior Vice President of Regulatory Affairs & Quality Assurance————

Sue Naim

Senior Vice President of Clinical Operations————

Venita De Almeida

Vice President & Head of Research Program Development————

Jeff E. Knight

Chief Development & Operating Officer—55800.00K0.59%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 17, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

1

$5.00M

Sells

7

$42,587.63

Net Transaction Value

+$4.96M

Net buying

Most Active

Pinto Shelly

3 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Aug 17, 26

Lettmann Jason

Direct

Sell$4.3K
Aug 17, 26

Wong Shelly

Direct

Sell$1.1K
Jul 1, 26

Wong Shelly

Direct

Sell$2.9K
Mar 19, 26

Lettmann Jason

Direct

Sell$26.7K
Mar 19, 26

Pinto Shelly

Direct

Sell$2K
Feb 18, 26

Pinto Shelly

Direct

Sell$1.3K
Feb 2, 26

GOODMAN COREY S

Indirect

Buy$5M
Jan 6, 26

Pinto Shelly

Direct

Sell$4.4K

Summary

Insiders reported 1 buys worth $5.00M and 7 sells worth $42,587.63 over the last 12 months. That adds up to net buying of $4.96M. Pinto Shelly was the most active insider with 3 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A2 analysts
RevenueN/AN/AN/A
N/A2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does ALX Oncology Holdings Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ALXO's management, answered from reported figures.

Who manages ALXO?

ALX Oncology Holdings Inc. (ALXO) lists 11 active executives. The top listed executive is Athanasios Tsiatis, Senior Vice President of Clinical Development.

Are ALXO insiders buying or selling?

Recent insider activity shows net buying of $24.04M.